newsfilter
← Latest News
PR Newswire·

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

  • Atossa Therapeutics (Nasdaq: ATOS) announced that Founder, Chairman, President, & CEO Steven Quay, M.D., Ph.D. was named one of "The Top 50 Healthcare Technology CEOs of 2025" by The Healthcare Technology Report.
  • Dr. Quay received the award for advancing innovative biotechnology solutions & building a high-performing, people-centered organization.
  • He has guided the development of (Z)-endoxifen, Atossa's lead precision-engineered endocrine therapy, across multiple Phase 2 clinical trials & the full breast cancer treatment continuum.
  • The therapy is optimized as a selective estrogen receptor modulator/degrader (SERM/D) with PKCβ1 inhibition to ensure consistent systemic exposure independent of CYP2D6 metabolism.
  • Atossa is also exploring (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD).
  • The award recognizes executives who drive innovation, lead through change, & translate science into real-world healthcare solutions.
  • Atossa emphasizes disciplined capital allocation to enable future regulatory submissions & potential commercialization of (Z)-Endoxifen.
  • The press release includes standard forward-looking statements regarding development milestones, regulatory approvals, & potential risks.